Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316, Bevacizumab, and Platinum in TNBC Brain Metastases
NCT04303988Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2020
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Mar 2020; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04303988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303988.